

To view this email as a web page, go [here](#).

[View in your browser](#)



INNOVATION AND COMMERCIALIZATION

Nov. 6, 2024

OHSU Innovates

LEADERSHIP MESSAGE

We are excited to share our latest OHSU Innovates 2024 Impact Report. This annual publication showcases the groundbreaking efforts of OHSU clinicians and scientists in the realms of commercialization, startups and collaborations. Inside the report, you will discover a variety of projects addressing diverse disease areas and types of innovation, including software-based diagnostics for ADHD and therapeutic vaccines for cancer. We hope you enjoy learning about these projects and are inspired to join the growing innovation community at OHSU.


Travis Cook, M.S., M.B.A, CLP

Senior Director, Technology Transfer

Aditi Martin, Ph.D.

Senior Director, Collaborations and Entrepreneurship

OHSU Innovates 2024 Impact Report



Check out the 2024 Impact Report to learn about new health care innovations being developed at OHSU. The report contains our annual innovation metrics and stories in four topic areas: revolutionizing eye care, improving behavioral health, developing new therapeutics for infectious diseases and improving cancer detection and prevention.

[Read the report](#)

NEWS

ProMedix secures \$200k investment at the Bend Venture Conference



Congratulations to OHSU startup company [ProMedix](#) and CEO Scott Filer on recently winning the growth stage category and taking home a \$200,000 investment at the 21st annual Bend Venture Conference, or BVC. ProMedix was co-founded by OHSU professors [David Sheridan, M.D.](#), and [Matt Hansen, M.D.](#), and is developing a noninvasive medical device that accelerates diagnosis of circulatory dysfunction and sepsis. Read more about the conference and the winners in the [Bend Venture Conference announcement](#).

New drug combinations could improve therapies for breast cancer

A recent publication from a team of OHSU researchers identified a combination of treatments that show promise in slowing the progression of cancer and reducing tumor growth. The research, led by senior co-authors [Sanjay Malhotra, Ph.D.](#), and [Lisa Coussens, Ph.D.](#), lays the groundwork for developing more effective treatments for triple negative breast cancers and mesotheliomas. Read more about the recent publication in the [OHSU News story](#).

Autobahn Therapeutics advances clinical trials for thyroid receptor targeting therapy

OHSU startup company [Autobahn Therapeutics](#) announced the initiation of a phase II clinical trial to evaluate ABX-002 as an adjunctive treatment for major depression disorder. ABX-002 is a highly potent, oral, thyroid hormone beta receptor (TR β) selective agonist originally developed in the laboratory of [Thomas Scanlan, Ph.D.](#) The company also obtained FDA clearance of an investigational new drug application for ABX-002 as an adjunctive treatment for bipolar depression. Read more about the latest ABX-002 clinical development news on the [Autobahn Therapeutics news page](#).

OHSU-led projects win at Oregon Biotech Summit's Innovation Showcase

Congratulations to the OHSU teams that won three out of the four pitch categories at the Biotech Summit and Innovation Showcase held by the Oregon Bioscience Association.

- [Matthew Rames, Ph.D.](#), won the translational research category for a project, run in collaboration with [Kai Tao, Ph.D.](#), developing new antibody conjugation strategies.
- [Peter Campbell, M.D., M.P.H.](#), won the late-stage company category for his pitch on the OHSU startup company [Siloam Vision](#).
- Matt Bryant won the early-stage company category for his presentation of Verendus Pharma, an OHSU startup company based on research from the laboratory of [Michael Cohen, Ph.D.](#)

Read more about the projects in the [OHSU Now post](#).

Two OHSU members elected to the National Academy of Medicine

Congratulations to [Lisa Coussens, Ph.D.](#), and [David Huang, M.D., Ph.D.](#), on recently being elected to the National Academy of Medicine. Election to the academy is considered one of the highest honors a scientist or clinician can receive in health

and medicine, and “recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.” Read more on the [OHSU News article](#).

Trace Biosciences opens new facility

Congratulations to OHSU startup company [Trace Biosciences](#), which recently opened new research facilities in Beaverton, Ore. Trace Biosciences is developing targeted imaging agents that highlight nerves in real time for surgery, and was co-founded by OHSU members Connor Barth, Ph.D., [Summer Gibbs, Ph.D.](#), and [Lei Wang, Ph.D.](#) Trace was also a semi-finalist in this year’s Bend Venture Conference pitch competition.

Watch the recording of the Innovates seminar “Advancing Care: Non-Profits Driving Rare Disease Research”

If you missed the last seminar from the OHSU Innovates Speaker Series on "Advancing Care: Non-profits driving rare disease research" you can catch the [recording on YouTube](#). This powerful session featured discussion about the challenges and strategies for funding rare disease research and innovations. Thank you again to our excellent speakers, [Penny Hogarth, M.D.](#), of the [Spoonbill Foundation](#) and Tommy Pham of the [Raiden Science Foundation](#).

ANNOUNCEMENTS

Holly Rockweiler joins the OHSU Entrepreneurs-in-Residence



Join us in welcoming Holly Rockweiler, M.S., as OHSU's newest entrepreneur-in-residence. Rockweiler is co-founder and CEO of Madorra, a women's health company dedicated to changing the treatment paradigm for vaginal atrophy and dryness. She co-founded Madorra as a spin-out of the Stanford Biodesign Fellowship. Prior to Biodesign, she worked as a senior research scientist at Boston Scientific where she developed therapies to enable more efficient care for patients living with heart failure. Her pre-clinical and clinical research has led to more than 20 pending and issued patents.

Laboratory Directed Research and Development grants awarded to researchers

Congratulations to the recently announced awardees of the Laboratory Directed Research and Development grants: [Rebecca Spain, M.D.](#), [Elinor Sullivan, Ph.D.](#), [Adel Kardosh, M.D., Ph.D.](#), and [Karina Nakayama, PhD](#). These grants were provided to support collaborative projects between Oregon Health & Science University and Pacific Northwest National Laboratory as part of the longstanding Pacific Northwest Biomedical Innovation Co-Laboratory partnership. Read more about the awardees in the [OHSU Now post](#).

Women entrepreneurs – apply now for the Equalize Startups pitch competition

Equalize Startups is a pitch competition and platform for coaching and promoting women academic inventors as they navigate the startup ecosystem and gain valuable connections. Applications are due Friday, Nov. 15. Find more information and apply on the [Equalize Startups website](#).

FEATURED EVENT

Angel Oregon Life & Bioscience Investment Announcement Mixer



DON'T MISS

**AOBIO
INVESTMENT
ANNOUNCEMENT
MIXER**

**THURS
NOV
21ST**

MISSION THEATER
1624 NW GLISAN
4:00 - 7:00 PM
OEN MEMBER: \$15
NON-MEMBER: \$25

OEN.ORG/PROGRAMS

Join the Oregon Entrepreneurs Network for the Angel Oregon Life & Bioscience, or AOBIO, Investment Announcement Mixer. This evening will celebrate innovations in the life and bioscience industry. AOBIO investors will also announce which of the finalists will receive the more than \$100,000 investment.

WHEN

Thursday, Nov. 21

4–7 p.m. PDT

WHERE

Mission Theater
1624 NW Glisan, Portland

COST

\$15 for OEN members, \$25 for non-members

REGISTRATION

Visit the [OEN website](#)

TECHNOLOGIES

Featured technologies available for licensing

A selection of OHSU-developed technologies available for licensing to industry partners. For more technologies visit the [OHSU Technology Portal](#).

[OHSU 3147](#) - Malaria transmission blocking using ELQ-infused bed nets

[OHSU 3300](#) - UVsynC: a sterilization drain cover for hospital sinks

Newly Licensed or Optioned OHSU Technologies

Congratulations to the inventors of these technologies, which were recently licensed or optioned to outside partners.

[OHSU 1771](#) - Materials from the BioLibrary

[OHSU 3191](#) - Workplace Mental Health Support Training for Leaders ([Leslie Hammer, Ph.D.](#))

U.S. Patents Issued

Congratulations to the OHSU inventors of these recently issued U.S. patents.

Patents [12,084,653](#) and [12,084,654](#) - Methods for using transcription-dependent directed evolution of AAV capsids

SPONSORS

Thank you to our current sponsors for their support of OHSU Innovates!



Questions? Contact us at innovates@ohsu.edu

This bi-monthly publication is created in collaboration with OHSU Technology Transfer, OHSU Collaborations and Entrepreneurship, Oregon Clinical and Translational Research Institute, School of Medicine and the Knight Cancer Institute.

©2024 OHSU

This email was sent by OHSU
3181 S.W. Sam Jackson Park Rd.
Portland, OR, 97239, US

This email was sent to: trueca@ohsu.edu
[Unsubscribe](#) | [Manage subscriptions](#) | [Update profile](#)
[OHSU email terms of service](#) | [OHSU privacy policy](#)